TherapeuticsMD, Inc. (TXMD) Financials
TXMD Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 37.5 million | 10.4 million |
| March 31, 2026 | 37.6 million | 10.6 million |
| Dec. 31, 2025 | 37.7 million | 10.8 million |
| Sept. 30, 2025 | 38.7 million | 11.2 million |
TXMD Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | 770000 | 6000 |
| March 31, 2026 | 936000 | 2000 |
| Dec. 31, 2025 | 368000 | 51000 |
| Sept. 30, 2025 | 1.0 million | ? |
TXMD Net Income
No data available :(
TXMD Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 9.2 million | - | 5.6 million |
| March 31, 2026 | 8.4 million | 4.8 million | 1.0 million |
| Dec. 31, 2025 | 7.5 million | - | 6.1 million |
| Sept. 30, 2025 | 7.1 million | - | 5.4 million |
TXMD Shares Outstanding
TXMD Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | - | - | 1.6 million | - |
| March 31, 2026 | - | - | 1.4 million | - |
| Dec. 31, 2025 | - | - | 2.3 million | - |
| Sept. 30, 2025 | - | - | 1.5 million | - |
TXMD Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 869000 | 329000 |
| March 31, 2026 | 724000 | 325000 |
| Dec. 31, 2025 | 893000 | 906000 |
| Sept. 30, 2025 | 784000 | 96000 |
TXMD Revenue by Segment
Graph available only for paid members. Upgrade to see it.
TXMD
Price: $2.16
52 week price:
Earnings Per Share: -0.03 USD
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Volume: 688
Ebitda: -21.6 millionMarket Capitalization: 25.6 million